Subject: New Eyes on ADVT this Week Add ADVT to your Watch list Now

SCV Client Spotlight
BY READING THIS EMAIL YOU CERTIFY YOU HAVE READ THE DISCLAIMER BELOW AND THE FULL DISCLAIMER PROVIDED THROUGH A LINK AT THE END OF THIS EMAIL. This is a paid advertisement., Inc. is not responsible or held liable for the information in the press releases issued by the companies in these emails. Please always do your own due diligence.
Facebook Twitter YouTube
New Eyes on ADVT this Week Add ADVT to your Watch list Now
Hot Stock to WatchHot Stock to Watch

Company: Advantis Corporation (Pink Sheets: ADVT)


Price: 0.004

Change (%): + 0.0003 (8.11)

Volume: 628,439

Recent News

Advantis CEO, Christopher Swartz, is Featured in an Exclusive New Interview at

AUSTIN, Texas, June 13, 2016 (GLOBE NEWSWIRE) -, Inc. (SCV) and ADVANTIS CORPORATION (OTC PINK:ADVT) or (the “Company”) announced today that a new audio interview with the Company, is now available. The interview can be heard at

Advantis CEO, Christopher Swartz, called in to, Inc. to discuss what his Company is working on 2016, the various markets they operate in and provide his personal insights to the exciting recent news for Advantis.

Recently Advantis announced that they engaged in a critical letter of intent with Hemp2Health, LLC, a Colorado company, to provide high grade CBD oil extract to Advantis for its product lines. Prior to that news they announced the hiring of Thomas Elgin, MD, as their Chief Medic. Dr. Elgin has worked in emergency medicine for fifteen years, and has extensive experience researching and developing nutraceuticals. CBD based nutraceuticals is the fastest growing sector within the medical marijuana business. Advantis CEO, Christopher Swartz, says that Dr. Elgin will additionally be responsible for testing the efficacy of products Advantis acquires and distributes. Swartz shares the doctor’s excitement about the future of CBD technology. “I am passionate about finding effective solutions to cure this chronic pain epidemic,” Swartz stated. “Dr. Elgin has been working with me at Sequence Therapy to develop proper exercises, and now at Advantis we will work together to develop effective medicines.”

Swartz, stated, “I enjoyed talking about the chronic pain problems we’re addressing for our target markets and our plans for 2016.’s audio presentations are disseminated through the web and to our shareholder base making it a powerful way to get our story to a wider audience.”

Continue Reading

Like Us on FacebookFollow Us on Twitter

SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, publicly available material information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that this information, which originates from third parties, is accurate. We do not have the resources to confirm the accuracy of all information obtained from third parties. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to, Inc. by companies featured on our website or in our e-mail communications.

About Penny Stocks